NCT03171220 (NRT-01) is a Phase 1, PHASE2 clinical trial of Neoantigen Reactive T Cells(NRTs) in Advanced Malignant Solid Tumor, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

What drugs are being tested in NCT03171220?

Interventions in NCT03171220: Neoantigen Reactive T Cells(NRTs), SHR-1210, Fludarabine, Cyclophosphamide, Interleukin-2.

What condition does NCT03171220 study?

NCT03171220 studies Advanced Malignant Solid Tumor.

Is NCT03171220 still recruiting?

NCT03171220 is currently status unknown. Last updated 6 June 2017.

Last reviewed 2017-06-06 · How we verify

NCT03171220: NRT-01

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors

Status unknown Phase 1, PHASE2 Last updated 6 June 2017

What this trial tests

Phase 1, PHASE2 trial testing Neoantigen Reactive T Cells(NRTs) in Advanced Malignant Solid Tumor in 40 participants. Status unknown.

Timeline

1 June 2017

Primary endpoint
31 December 2019

31 December 2020

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	1 June 2017
Primary completion	31 December 2019
Estimated completion	31 December 2020
Sites	1 location across China

Drugs / interventions tested

Neoantigen Reactive T Cells(NRTs) — full drug profile →
SHR-1210 — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →
Interleukin-2

Conditions studied

Advanced Malignant Solid Tumor — all drugs for Advanced Malignant Solid Tumor →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 18 to 75, any sex, with Advanced Malignant Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to see the safety and efficient of neoantigen reactive T cells (NRTs) combined with programmed cell death-1(PD-1) inhibitor（SHR-1210）in the treatment of Chinese patients with advanced refractory solid tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Neoantigens: promising targets for cancer therapy.
Xie N, Shen G, Gao W, Huang Z, et al · · 2023 · cited 713× · PMID 36604431 · DOI 10.1038/s41392-022-01270-x
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics.
Garg AD, More S, Rufo N, Mece O, et al · · 2017 · cited 206× · PMID 29209573 · DOI 10.1080/2162402x.2017.1386829
Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F, Zou Z, Du J, Su S, et al · · 2019 · cited 184× · PMID 30835255 · DOI 10.1172/jci99538
Progress in Neoantigen Targeted Cancer Immunotherapies.
Han XJ, Ma XL, Yang L, Wei YQ, et al · · 2020 · cited 37× · PMID 32850843 · DOI 10.3389/fcell.2020.00728
Engineering neoantigen vaccines to improve cancer personalized immunotherapy.
Liu Z, Lv J, Dang Q, Liu L, et al · · 2022 · cited 30× · PMID 36263174 · DOI 10.7150/ijbs.76281
Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
Okada M, Shimizu K, Fujii SI. · · 2022 · cited 28× · PMID 35269735 · DOI 10.3390/ijms23052594
New insights into the stemness of adoptively transferred T cells by γc family cytokines.
Luo M, Gong W, Zhang Y, Li H, et al · · 2023 · cited 12× · PMID 38049832 · DOI 10.1186/s12964-023-01354-3
Adoptive neoantigen-reactive T cell therapy: improvement strategies and current clinical researches.
Huang R, Zhao B, Hu S, Zhang Q, et al · · 2023 · cited 8× · PMID 37062844 · DOI 10.1186/s40364-023-00478-5

Verify or expand the search:

Other trials of Neoantigen Reactive T Cells(NRTs)

Trials testing the same drug.

NCT06432075 — Neoantigen Reactive T Cells c for Chinese Patients With Advanced Gastric Cancer · EARLY_PHASE1 · not yet recruiting

Other recruiting trials for Advanced Malignant Solid Tumor

Currently open trials in the same condition.

NCT07293754 — An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07050641 — Phase I/II Study of SCTB39-1 in Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
NCT06718946 — Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT06592417 — To Evaluate the Phase I Clinical Study of JSKN016 in Chinese Patients With Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT05477849 — A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with S · Phase 1 · recruiting

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03171220 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 6 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03171220.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing